Teva Pharmaceutical Industries (NYSE:TEVA) Earns Overweight Rating from Piper Sandler

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “overweight” rating restated by equities research analysts at Piper Sandler in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $41.00 price target on the stock, up from their prior price target of $40.00. Piper Sandler’s target price indicates a potential upside of 26.90% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Bank of America raised their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. The Goldman Sachs Group increased their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Finally, Scotiabank upped their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $32.31 on Wednesday. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The firm’s fifty day simple moving average is $33.01 and its 200-day simple moving average is $26.02. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The stock has a market cap of $37.15 billion, a PE ratio of 26.93, a price-to-earnings-growth ratio of 11.30 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the sale, the executive vice president directly owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. This trade represents a 85.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Roberto Mignone sold 77,400 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the sale, the director directly owned 367,600 shares in the company, valued at $11,116,224. This trade represents a 17.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 767,870 shares of company stock valued at $23,888,014 over the last three months. Company insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Global Retirement Partners LLC increased its position in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the last quarter. Captrust Financial Advisors grew its stake in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock valued at $459,000 after purchasing an additional 302 shares in the last quarter. Banque Cantonale Vaudoise increased its holdings in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after purchasing an additional 306 shares during the last quarter. Ethic Inc. raised its position in shares of Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after purchasing an additional 325 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.